Drug Profile
BIM 23268
Alternative Names: BIM 23268DLatest Information Update: 04 May 2007
Price :
$50
*
At a glance
- Originator Biomeasure Inc
- Class
- Mechanism of Action Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 25 Aug 2003 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
- 03 Jun 2003 Beaufour-Ipsen is now called Ipsen
- 12 Dec 2001 Preclinical development for Type-2 diabetes mellitus in USA (Unknown route)